REGAL Reports an Overall Survival Gain in AML

SELLAS reported that the randomized Phase 3 REGAL trial met its prespecified overall-survival endpoint in 126 adults with AML in second or later remission who could not undergo allogeneic transplant. GPS versus investigator-choice treatment…




